comparemela.com

Page 6 - Hans Vassg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ultimovacs ASA - Contemplated private placement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN

South africaUnited statesUnited kingdomRadforsk investeringstiftelseAdvokatfirmaet schjJoachim midttunSundal collierHans vassgOslo stock exchange guidelinesFinancial servicesGjelsten holdingCompany boardCompany board of directors theOslo stock exchangeBoard of directors the companyLaunch phase

Ultimovacs ASA: Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)

Fifth Phase II trial of UV1 in cancer, and largest disease category to dateUV1 will be investigated in combination with the standard-of-care pembrolizumabExpected data read-out by end of 2024 Oslo

Joachim midttunMary ann changHans vassgTerje brustugunFifth phaseCarlos de sousaOdd terje brustugunDrammen hospitalTodd terjeFast trackAnn changAbuse regulationNorwegian securities tradingFinance manager

Ultimovacs ASA - Private placement of new shares successfully placed

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

South africaUnited statesUnited kingdomAdvokatfirmaet schjSundal collierHans vassgOslo stock exchange guidelinesFinancial servicesOslo stock exchangeGjelsten holdingPrivate placementOffer sharesJoint bookrunnersNorwegian securities trading actOslo rule bookAdvokatfirmaet wiersholm

Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Mary ann changHans vassgFast trackRolling reviewBiologic licenseAccelerated approvalPriority reviewCarlos de sousaChief executive officerAnn changLifesci advisorsGlobe newswireUltimovacs asa

Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Mary ann changHans vassgChief medical officerCarlos de sousaAnn changLifesci advisorsUltimovacs asaClinical trialsGlobe newswire

vimarsana © 2020. All Rights Reserved.